本帖最后由 老马 于 2013-3-13 13:43 编辑
! f. ^. B$ r/ H( F- K
0 q) @* i$ P9 {8 F# B0 f健择(吉西他滨)+顺铂+阿瓦斯汀
: g6 `( `2 |' F Gemzar +Cisplatin + Avastin
7 b' R% e$ i1 d$ W; R% j2 J% ahttp://annonc.oxfordjournals.org/content/21/9/1804.full
# v5 O$ H. @; V+ b6 D, }* DOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) 8 S, ?+ Y3 i" u/ g' P2 N5 K
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. K# ?) u6 f7 O; [' m
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. " S) c* j& T4 P; Q& e* f
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 979)
7 C. M. M3 N% r g; v2 p& B华为网盘附件:# j# p, x; h* {0 n+ u% A1 \& W0 D
【华为网盘】ava.JPG
1 s! J. z9 Z- q0 B) ]3 V/ P# z' w3 ^ |